Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Helical is the virtual AI lab for pharma, designed to turn bio foundation models into reproducible discovery systems.
-
BGB Group appoints Julie Yoon Chief Client Officer to strengthen client engagement & deliver breakthrough thinking across the commercialization lifecycle.
-
Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
-
AscellaHealth Named to Financial Times Americas’ Fastest Growing Companies 2026 List
-
Alira Health today released its sixth annual report on the state of the contract development and manufacturing organization (CDMO) market in medtech.
-
Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...
-
Hyderabad, India, March 30, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the artificial intelligence in drug discovery market size was valued at USD 2.58 billion in 2025 and is...
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
Neion Bio exits stealth with first biosimilar co-development and supply partnership, leveraging its genetic engineering platform to enable scalable, lower-
-
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist